State of Illinois
91st General Assembly
Legislation

   [ Search ]   [ Legislation ]
[ Home ]   [ Back ]   [ Bottom ]


[ Introduced ][ Engrossed ][ House Amendment 001 ]
[ Senate Amendment 001 ][ Senate Amendment 002 ]

91_SB0013enr

 
SB13 Enrolled                                 LRB9100300RCksA

 1        AN ACT to amend the Illinois Controlled Substances Act by
 2    changing  Sections 309, 312, 313, and 406, by adding Sections
 3    316, 317, 318, 319, and 320 and repealing Sections 308,  310,
 4    and 311.

 5        Be  it  enacted  by  the People of the State of Illinois,
 6    represented in the General Assembly:

 7        Section 5. The  Illinois  Controlled  Substances  Act  is
 8    amended  by  changing  Sections 309, 312, 313, and 406 and by
 9    adding Sections 316, 317, 318, 319, and 320 as follows:

10        (720 ILCS 570/309) (from Ch. 56 1/2, par. 1309)
11        Sec. 309.   No person shall issue a  prescription  for  a
12    Schedule  II  controlled  substance, which is a narcotic drug
13    listed in Section 206 of this  Act;  or  which  contains  any
14    quantity  of  amphetamine  or  methamphetamine,  their salts,
15    optical isomers or salts of  optical  isomers;  phenmetrazine
16    and  its  salts;  gluthethimide;  pentazocine;  or  which  is
17    hereafter determined to be a "designated product," as defined
18    in  Section  102  of  this  Act,  other than on a written the
19    official prescription blank issued by the Department  and  no
20    person  shall  fill  any  such prescription other than on the
21    official  prescription  blank  issued  by   the   Department;
22    provided  that  in  the  case  of an emergency, epidemic or a
23    sudden or unforeseen accident or calamity, the prescriber may
24    issue a lawful oral prescription or  transmit  via  facsimile
25    equipment   a   written   prescription  order  or  a  written
26    prescription on a blank other than the official  prescription
27    blank  issued by the Department where failure to issue such a
28    prescription  might  result  in  loss  of  life  or   intense
29    suffering,   but  such  oral  prescription  shall  include  a
30    statement have endorsed thereon by the prescriber a statement
31      concerning  the  accident  or  calamity,  or  circumstances
 
SB13 Enrolled              -2-                LRB9100300RCksA
 1    constituting the emergency,  the  cause  for  which  an  oral
 2    prescription the unofficial blank was used.  Within 7 days 72
 3    hours after issuing an emergency prescription, the prescriber
 4    shall   cause   a   written   prescription  on  the  official
 5    prescription blank for the emergency quantity  prescribed  to
 6    be  delivered to the dispensing pharmacist.  The prescription
 7    shall have written on its face "Authorization  for  Emergency
 8    Dispensing",  and the date of the emergency prescription. The
 9    written prescription on the official prescription  blank  may
10    be  delivered  to the pharmacist in person, or by mail or via
11    facsimile equipment, but if delivered  by  mail  it  must  be
12    postmarked within the 7-day 72-hour period. Upon receipt, the
13    dispensing  pharmacist  shall attach this prescription to the
14    emergency oral prescription earlier received and , or in  the
15    case  of  an  oral  prescription,  reduced  to  writing.  The
16    dispensing pharmacist shall notify the  Department  of  Human
17    Services if the prescriber fails to deliver the authorization
18    for  emergency  dispensing on the official prescription blank
19    to him.  Failure of the dispensing pharmacist to do so  shall
20    void  the  authority  conferred by this paragraph to dispense
21    without a written prescription on  an  official  prescription
22    blank  of  a  prescriber.  All  prescriptions on the official
23    blanks shall be written in triplicate and  all  three  copies
24    signed  by  the  prescriber.   All  prescriptions  issued for
25    Schedule  II  controlled  substances  shall  include  both  a
26    written and numerical notation of quantity on the face of the
27    prescription.  No prescription for a Schedule  II  controlled
28    substance may be refilled.
29    (Source: P.A. 89-202, eff. 10-1-95; 89-507, eff. 7-1-97.)

30        (720 ILCS 570/312) (from Ch. 56 1/2, par. 1312)
31        Sec.   312.    Requirements   for  dispensing  controlled
32    substances.
33        (a)  A  practitioner,  in  good  faith,  may  dispense  a
 
SB13 Enrolled              -3-                LRB9100300RCksA
 1    Schedule II controlled substance, which is  a  narcotic  drug
 2    listed  in  Section  206  of  this Act; or which contains any
 3    quantity of  amphetamine  or  methamphetamine,  their  salts,
 4    optical  isomers  or  salts of optical isomers; phenmetrazine
 5    and its salts; pentazocine; or which is hereafter  determined
 6    to  be  a  "designated product," as defined in Section 102 of
 7    this Act to any person upon an official prescription form and
 8    Schedule III, IV, or V controlled substances  to  any  person
 9    upon  a  written  prescription  of  any prescriber, dated and
10    signed by the person prescribing on the day when  issued  and
11    bearing  the name and address of the patient for whom, or the
12    owner of the animal for which  the  controlled  substance  is
13    dispensed,  and  the  full  name, address and registry number
14    under the laws of the United States  relating  to  controlled
15    substances of the prescriber, if he is required by those laws
16    to  be  registered.  If  the prescription is for an animal it
17    shall state the species of animal for which  it  is  ordered.
18    The  practitioner  filling  the  prescription shall write the
19    date of filling and his own signature  on  the  face  of  the
20    written official prescription form. The official prescription
21    form or the written prescription shall be retained on file by
22    the  practitioner  who  filled  it  or  pharmacy in which the
23    prescription was filled for a period of 2 years, so as to  be
24    readily  accessible  for inspection or removal by any officer
25    or employee engaged in the enforcement of this Act.  Whenever
26    the practitioner's or pharmacy's  copy  of  any  prescription
27    form  is  removed  by  an  officer or employee engaged in the
28    enforcement of this Act, for the purpose of investigation  or
29    as  evidence,  such  officer  or  employee  shall give to the
30    practitioner  or  pharmacy  a  receipt  in  lieu  thereof.  A
31    prescription form for  a  Schedule  II  controlled  substance
32    shall  not  be  filled  more  than  7  days after the date of
33    issuance.  A written prescription for Schedule III, IV  or  V
34    controlled  substances  shall  not be filled or refilled more
 
SB13 Enrolled              -4-                LRB9100300RCksA
 1    than 6 months after the date thereof or refilled more than  5
 2    times unless renewed, in writing, by the prescriber.
 3        (b)  In  lieu  of a written prescription required by this
 4    Section, a pharmacist, in good faith, may  dispense  Schedule
 5    III,  IV, or V substances to any person either upon receiving
 6    a facsimile of a written, signed prescription transmitted  by
 7    the  prescriber  or  the  prescriber's agent or upon a lawful
 8    oral prescription of a  prescriber  which  oral  prescription
 9    shall  be  reduced  promptly to writing by the pharmacist and
10    such written memorandum thereof shall be  dated  on  the  day
11    when such oral prescription is received by the pharmacist and
12    shall bear the full name and address of the ultimate user for
13    whom,  or of the owner of the animal for which the controlled
14    substance is dispensed,  and  the  full  name,  address,  and
15    registry  number  under the law of the United States relating
16    to controlled substances of the prescriber prescribing if  he
17    is  required  by  those  laws  to  be  so registered, and the
18    pharmacist filling such oral  prescription  shall  write  the
19    date  of  filling  and  his own signature on the face of such
20    written  memorandum  thereof.   The  facsimile  copy  of  the
21    prescription or written memorandum of the  oral  prescription
22    shall  be  retained on file by the proprietor of the pharmacy
23    in which it is filled for a  period  of  not  less  than  two
24    years,  so  as to be readily accessible for inspection by any
25    officer or employee engaged in the enforcement of this Act in
26    the same manner as a  written  prescription.   The  facsimile
27    copy of the prescription or oral prescription and the written
28    memorandum  thereof shall not be filled or refilled more than
29    6 months after the date thereof or be refilled  more  than  5
30    times, unless renewed, in writing, by the prescriber.
31        (c)  A  controlled substance included in Schedule V shall
32    not be distributed or dispensed  other  than  for  a  medical
33    purpose  and  not  for  the  purpose of evading this Act, and
34    then:
 
SB13 Enrolled              -5-                LRB9100300RCksA
 1             (1)  only  personally  by  a  person  registered  to
 2        dispense a Schedule V controlled substance and then  only
 3        to his patients, or
 4             (2)  only  personally by a pharmacist, and then only
 5        to a person over 21  years  of  age  who  has  identified
 6        himself   to  the  pharmacist  by  means  of  2  positive
 7        documents of identification.
 8             (3)  the dispenser shall record the name and address
 9        of the purchaser, the name and quantity of  the  product,
10        the  date  and  time  of  the  sale,  and the dispenser's
11        signature.
12             (4)  no person shall purchase or be  dispensed  more
13        than  120  milliliters  or  more  than  120  grams of any
14        Schedule   V   substance    which    contains    codeine,
15        dihydrocodeine,  or  any salts thereof, or ethylmorphine,
16        or any  salts  thereof,  in  any  96  hour  period.   The
17        purchaser  shall  sign a form, approved by the Department
18        of Professional Regulation, attesting  that  he  has  not
19        purchased any Schedule V controlled substances within the
20        immediately preceding 96 hours.
21             (5)  a  copy  of  the records of sale, including all
22        information required by paragraph (3), shall be forwarded
23        to the  Department  of  Professional  Regulation  at  its
24        principal office by the 15th day of the following month.
25             (6)  all  records  of  purchases  and sales shall be
26        maintained for not less than 2 years.
27             (7)  no person shall obtain  or  attempt  to  obtain
28        within  any  consecutive  96  hour  period any Schedule V
29        substances of more than 120 milliliters or more than  120
30        grams  containing  codeine,  dihydrocodeine or any of its
31        salts, or ethylmorphine or any of its salts.  Any  person
32        obtaining   any   such  preparations  or  combination  of
33        preparations in excess of this  limitation  shall  be  in
34        unlawful possession of such controlled substance.
 
SB13 Enrolled              -6-                LRB9100300RCksA
 1             (8)  a   person  qualified  to  dispense  controlled
 2        substances under this Act and registered thereunder shall
 3        at no time maintain  or  keep  in  stock  a  quantity  of
 4        Schedule  V  controlled  substances defined and listed in
 5        Section 212 (b) (1), (2) or (3) in excess of  4.5  liters
 6        for  each substance; a pharmacy shall at no time maintain
 7        or keep in stock a  quantity  of  Schedule  V  controlled
 8        substances  as  defined  in excess of 4.5 liters for each
 9        substance, plus the  additional  quantity  of  controlled
10        substances  necessary  to  fill  the  largest  number  of
11        prescription  orders  filled  by  that  pharmacy for such
12        controlled substances in any one  week  in  the  previous
13        year.   These  limitations  shall not apply to Schedule V
14        controlled substances which Federal  law  prohibits  from
15        being dispensed without a prescription.
16             (9)  no  person  shall  distribute or dispense butyl
17        nitrite for inhalation or  other  introduction  into  the
18        human body for euphoric or physical effect.
19        (d)  Every practitioner shall keep a record of controlled
20    substances   received  by  him  and  a  record  of  all  such
21    controlled    substances    administered,    dispensed     or
22    professionally  used  by  him otherwise than by prescription.
23    It  shall,  however,  be  sufficient  compliance  with   this
24    paragraph if any practitioner utilizing controlled substances
25    listed  in Schedules III, IV and V shall keep a record of all
26    those substances dispensed and distributed by him other  than
27    those  controlled  substances  which  are administered by the
28    direct application of  a  controlled  substance,  whether  by
29    injection,  inhalation,  ingestion, or any other means to the
30    body of a patient or research  subject.  A  practitioner  who
31    dispenses,   other   than   by  administering,  a  controlled
32    substance in Schedule II, which is a narcotic drug listed  in
33    Section  206  of  this Act, or which contains any quantity of
34    amphetamine or methamphetamine, their salts, optical  isomers
 
SB13 Enrolled              -7-                LRB9100300RCksA
 1    or  salts  of  optical isomers, pentazocine, methaqualone, or
 2    which is hereafter determined to be a "designated product" as
 3    defined in Section 102 of this Act, shall do so only upon the
 4    issuance of a written an official  prescription  blank  by  a
 5    prescriber;  and  every  practitioner  who  so dispenses such
 6    designated products  shall  comply  with  the  provisions  of
 7    Sections 310 and 311 of this Act.
 8        (e)  Whenever  a  manufacturer  distributes  a controlled
 9    substance in a  package  prepared  by  him,  and  whenever  a
10    wholesale distributor distributes a controlled substance in a
11    package  prepared  by  him  or  the  manufacturer,  he  shall
12    securely  affix  to  each  package in which that substance is
13    contained a label showing in legible  English  the  name  and
14    address   of   the  manufacturer,  the  distributor  and  the
15    quantity, kind and form  of  controlled  substance  contained
16    therein.   No  person  except  a  pharmacist and only for the
17    purposes of filling a  prescription  under  this  Act,  shall
18    alter, deface or remove any label so affixed.
19        (f)  Whenever  a  practitioner  dispenses  any controlled
20    substance, he shall affix to  the  container  in  which  such
21    substance  is  sold or dispensed, a label indicating the date
22    of initial filling, the practitioner's name and address,  the
23    serial  number  of the prescription, the name of the patient,
24    the name of  the  prescriber,  the  directions  for  use  and
25    cautionary  statements, if any, contained in any prescription
26    or required by law, the proprietary  name  or  names  or  the
27    established  name of the controlled substance, and the dosage
28    and quantity, except as otherwise authorized by regulation by
29    the Department of Professional Regulation.  No  person  shall
30    alter, deface or remove any label so affixed.
31        (g)  A  person  to  whom  or for whose use any controlled
32    substance has been prescribed or dispensed by a practitioner,
33    or other persons authorized under this Act, and the owner  of
34    any  animal  for  which such substance has been prescribed or
 
SB13 Enrolled              -8-                LRB9100300RCksA
 1    dispensed  by  a  veterinarian,  may  lawfully  possess  such
 2    substance only in the container in which it was delivered  to
 3    him by the person dispensing such substance.
 4        (h)  The  responsibility  for  the  proper prescribing or
 5    dispensing of controlled substances is  upon  the  prescriber
 6    and   the   responsibility   for  the  proper  filling  of  a
 7    prescription for controlled substance drugs  rests  with  the
 8    pharmacist.   An order purporting to be a prescription issued
 9    to any individual, which is not  in  the  regular  course  of
10    professional  treatment  nor  part of an authorized methadone
11    maintenance  program,  nor  in  legitimate   and   authorized
12    research  instituted  by any accredited hospital, educational
13    institution, charitable  foundation,  or  federal,  state  or
14    local  governmental  agency, and which is intended to provide
15    that individual  with  controlled  substances  sufficient  to
16    maintain that individual's or any other individual's physical
17    or   psychological  addiction,  habitual  or  customary  use,
18    dependence, or diversion of that controlled substance is  not
19    a prescription within the meaning and intent of this Act; and
20    the  person  issuing  it,  shall  be subject to the penalties
21    provided for violations of the  law  relating  to  controlled
22    substances.
23        (i)  A  prescriber  shall  not  preprint  or  cause to be
24    preprinted a prescription for any controlled  substance;  nor
25    shall  any  practitioner issue, fill or cause to be issued or
26    filled,  a  preprinted  prescription   for   any   controlled
27    substance.
28        (j)  No  person  shall  manufacture,  dispense,  deliver,
29    possess  with  intent to deliver, prescribe, or administer or
30    cause to be administered under  his  direction  any  anabolic
31    steroid,  for  any  use in humans other than the treatment of
32    disease in accordance with the order of a physician  licensed
33    to  practice medicine in all its branches for a valid medical
34    purpose in the course of professional practice.  The  use  of
 
SB13 Enrolled              -9-                LRB9100300RCksA
 1    anabolic  steroids  for  the purpose of hormonal manipulation
 2    that is intended to increase muscle mass, strength or  weight
 3    without  a  medical  necessity  to do so, or for the intended
 4    purpose of improving physical appearance  or  performance  in
 5    any  form of exercise, sport, or game, is not a valid medical
 6    purpose or in the course of professional practice.
 7    (Source: P.A. 89-202, eff. 10-1-95; 90-253, eff. 7-29-97.)

 8        (720 ILCS 570/313) (from Ch. 56 1/2, par. 1313)
 9        Sec. 313.  (a) Controlled substances which  are  lawfully
10    administered  in hospitals or institutions licensed under the
11    "Hospital  Licensing  Act"   shall   be   exempt   from   the
12    requirements  of Sections 308 and 312 and 316 except that the
13    prescription for the controlled substance shall be in writing
14    on the patient's record, signed by the prescriber, dated, and
15    shall state the name, and quantity of  controlled  substances
16    ordered  and  the quantity actually administered. The records
17    of such prescriptions shall be maintained for two  years  and
18    shall  be  available for inspection by officers and employees
19    of the Department of State  Police,  and  the  Department  of
20    Professional Regulation.
21        (b)  Controlled   substances   that   can   lawfully   be
22    administered   or  dispensed  directly  to  a  patient  in  a
23    long-term care facility licensed by the Department of  Public
24    Health  as  a  skilled  nursing  facility,  intermediate care
25    facility, or long-term care facility for residents  under  22
26    years  of  age,  are exempt from the requirements of Sections
27    308 and 312 and 316. ,  except  that  a  prescription  for  a
28    Schedule  II  controlled  substance  must be either a written
29    prescription  signed  by  the   prescriber   or   a   written
30    prescription  transmitted  by  the prescriber or prescriber's
31    agent to the dispensing pharmacy by facsimile.  The facsimile
32    serves as the  original  written  prescription  and  must  be
33    maintained  for  2  years  from the date of issue in the same
 
SB13 Enrolled              -10-               LRB9100300RCksA
 1    manner as a written prescription signed by the prescriber.
 2        (c)  (Blank).  A  prescription  that  is  written  for  a
 3    Schedule II controlled substance to be compounded for  direct
 4    administration  by  parenteral,  intravenous,  intramuscular,
 5    subcutaneous,  or  intraspinal  infusion  to  a  patient in a
 6    private  residence,  long-term  care  facility,  or   hospice
 7    setting  may be transmitted by facsimile by the prescriber or
 8    the prescriber's agent to the  pharmacy  providing  the  home
 9    infusion services.
10        (d)  Controlled    substances    which    are    lawfully
11    administered   and/or   dispensed  in  drug  abuse  treatment
12    programs licensed by the Department shall be exempt from  the
13    requirements of Sections 308 and 312 and 316, except that the
14    prescription  for  such controlled substances shall be issued
15    and authenticated on official prescription logs prepared  and
16    supplied  by  the  Department. The official prescription logs
17    issued by the Department shall be printed  in  triplicate  on
18    distinctively  marked  paper  and  furnished  to  programs at
19    reasonable cost.  The official prescription logs furnished to
20    the  programs  shall  contain,  in  preprinted   form,   such
21    information  as  the  Department  may  require.  The official
22    prescription logs shall be properly endorsed by  a  physician
23    licensed to practice medicine in all its branches issuing the
24    order,  with  his own signature and the date of ordering, and
25    further endorsed by the practitioner  actually  administering
26    or dispensing the dosage at the time of such administering or
27    dispensing  in  accordance  with  requirements  issued by the
28    Department.  The duplicate copy  shall  be  retained  by  the
29    program  for  a  period of not less than three years nor more
30    than seven years; the original and triplicate copy  shall  be
31    returned  to  the  Department  at  its  principal  office  in
32    accordance with requirements set forth by the Department.
33    (Source: P.A. 89-202, eff. 10-1-95.)
 
SB13 Enrolled              -11-               LRB9100300RCksA
 1        (720 ILCS 570/316 new)
 2        Sec.  316.  Schedule II Controlled substance prescription
 3    monitoring program.
 4        The Department must provide for a Schedule II  controlled
 5    substance  prescription  monitoring program that includes the
 6    following components:
 7        (1)  Each  time  a  Schedule  II   controlled   substance
 8    designated by the Department is dispensed, the dispenser must
 9    transmit to the central repository the following information:
10             (A)  The recipient's name.
11             (B)  The recipient's address.
12             (C)  The  national  drug code number of the Schedule
13        II controlled substance dispensed.
14             (D)  The date the Schedule II  controlled  substance
15        is dispensed.
16             (E)  The  quantity  of  the  Schedule  II controlled
17        substance dispensed.
18             (F)  The dispenser's United States Drug  Enforcement
19        Agency registration number.
20             (G)  The prescriber's United States Drug Enforcement
21        Agency registration number.
22        (2)  The  information  required  to  be transmitted under
23    this Section must be transmitted not more than 15 days  after
24    the  date  on  which  a  Schedule  II controlled substance is
25    dispensed.
26        (3)  A dispenser must transmit the  information  required
27    under this Section by:
28             (A)  an   electronic   device  compatible  with  the
29        receiving device of the central repository;
30             (B)  a computer diskette;
31             (C)  a magnetic tape; or
32             (D)  a pharmacy universal  claim  form  or  Pharmacy
33        Inventory Control form;
34    that meets specifications prescribed by the Department.
 
SB13 Enrolled              -12-               LRB9100300RCksA
 1        Schedule  II  controlled  substances  are exempt from the
 2    requirements of  this  Section  to  the  extent  provided  in
 3    Section 313.

 4        (720 ILCS 570/317 new)
 5        Sec.   317.   Central   repository   for   collection  of
 6    information.
 7        (a) The Department must designate  a  central  repository
 8    for  the  collection of information transmitted under Section
 9    316.
10        (b) The central repository must do the following:
11             (1)  Create a database for information  required  to
12        be  transmitted  under  Section  316 in the form required
13        under rules adopted by the Department,  including  search
14        capability for the following:
15                  (A) A recipient's name.
16                  (B) A recipient's address.
17                  (C)   The   national  drug  code  number  of  a
18             controlled substance dispensed.
19                  (D)  The  dates  a   Schedule   II   controlled
20             substance is dispensed.
21                  (E)  The quantities of a Schedule II controlled
22             substance dispensed.
23                  (F)   A   dispenser's   United   States    Drug
24             Enforcement Agency registration number.
25                  (G)   A   prescriber's   United   States   Drug
26             Enforcement Agency registration number.
27             (2) Provide the Department with continuing 24 hour a
28        day  on-line  access  to  the  database maintained by the
29        central  repository.   The  Department  of   Professional
30        Regulation  must  provide  the Department with electronic
31        access to the license  information  of  a  prescriber  or
32        dispenser.  The Department of Professional Regulation may
33        charge  a  fee  for  this access not to exceed the actual
 
SB13 Enrolled              -13-               LRB9100300RCksA
 1        cost of furnishing the information.
 2             (3) Secure the information collected by the  central
 3        repository  and  the  database  maintained by the central
 4        repository against access by unauthorized persons.

 5        (720 ILCS 570/318 new)
 6        Sec. 318. Confidentiality of information.
 7        (a)  Information received by the central repository under
 8    Section 316 is confidential.
 9        (b) The Department must carry out a  program  to  protect
10    the   confidentiality   of   the   information  described  in
11    subsection (a). The Department may disclose  the  information
12    to  another person only under subsection (c), (d), or (f) and
13    may charge a fee not to exceed the actual cost of  furnishing
14    the information.
15        (c)  The Department may disclose confidential information
16    described in subsection (a) to any person who is  engaged  in
17    receiving, processing, or storing the information.
18        (d)  The  Department may release confidential information
19    described in subsection (a) to the following persons:
20             (1) A governing body that licenses practitioners and
21        is engaged in an investigation,  an  adjudication,  or  a
22        prosecution of a violation under any State or federal law
23        that involves a controlled substance.
24             (2)  An  investigator  for  the  Consumer Protection
25        Division  of  the  office  of  the  Attorney  General,  a
26        prosecuting attorney,  the  Attorney  General,  a  deputy
27        Attorney  General,  or an investigator from the office of
28        the Attorney General,  who  is  engaged  in  any  of  the
29        following activities involving controlled substances:
30                  (A) an investigation;
31                  (B) an adjudication; or
32                  (C)  a  prosecution  of  a  violation under any
33             State or federal  law  that  involves  a  controlled
 
SB13 Enrolled              -14-               LRB9100300RCksA
 1             substance.
 2             (3) A law enforcement officer who is:
 3                  (A)  authorized  by  the  Department  of  State
 4             Police  to receive information of the type requested
 5             for  the   purpose   of   investigations   involving
 6             controlled substances;
 7                  (B)  approved  by  the  Department  to  receive
 8             information of the type requested for the purpose of
 9             investigations involving controlled substances; and
10                  (C) engaged in the investigation or prosecution
11             of  a  violation under any State or federal law that
12             involves a controlled substance.
13        (e)   Before   the   Department   releases   confidential
14    information  under  subsection  (d),   the   applicant   must
15    demonstrate to the Department that:
16             (1)  the  applicant  has  reason  to  believe that a
17        violation under any State or federal law that involves  a
18        Schedule II controlled substance has occurred; and
19             (2)  the requested information is reasonably related
20        to the investigation, adjudication, or prosecution of the
21        violation described in subdivision (1).
22        (f) The Department may release to:
23             (1) a governing body that licenses practitioners;
24             (2) an  investigator  for  the  Consumer  Protection
25        Division  of  the  office  of  the  Attorney  General,  a
26        prosecuting  attorney,  the  Attorney  General,  a deputy
27        Attorney General, or an investigator from the  office  of
28        the Attorney General; or
29             (3) a law enforcement officer who is:
30                  (A)  authorized  by  the  Department  of  State
31             Police  to receive the type of information released;
32             and
33                  (B) approved by the Department to  receive  the
34             type of information released;
 
SB13 Enrolled              -15-               LRB9100300RCksA
 1    confidential information generated from computer records that
 2    identifies  practitioners  who  are prescribing or dispensing
 3    large quantities of a Schedule  II  controlled  substance  as
 4    determined by the Advisory Committee created by Section 320.
 5        (g)  The  information described in subsection (f) may not
 6    be released until it has been reviewed by an employee of  the
 7    Department  who  is  licensed as a  prescriber or a dispenser
 8    and  until  that  employee   has   certified   that   further
 9    investigation  is  warranted. However, failure to comply with
10    this subsection (g)  does  not  invalidate  the  use  of  any
11    evidence   that  is  otherwise  admissible  in  a  proceeding
12    described in subsection (h).
13        (h)  An  investigator  or  a  law   enforcement   officer
14    receiving confidential information under subsection (c), (d),
15    or  (f)  may  disclose  the  information to a law enforcement
16    officer or an attorney for the office of the Attorney General
17    for use as evidence in the following:
18             (1) A proceeding under any State or federal law that
19        involves a Schedule II controlled substance.
20             (2)  A  criminal  proceeding  or  a  proceeding   in
21        juvenile  court  that  involves  a Schedule II controlled
22        substance.
23        (i) The Department may compile statistical  reports  from
24    the information described in subsection (a). The reports must
25    not  include  information  that  identifies any practitioner,
26    ultimate user, or other  person  administering  a  controlled
27    substance.

28        (720 ILCS 570/319 new)
29        Sec.  319.  Rules.  The Department must adopt rules under
30    the  Illinois  Administrative  Procedure  Act  to   implement
31    Sections 316 through 318, including the following:
32             (1)  Information collection and retrieval procedures
33        for the central repository,  including  the  Schedule  II
 
SB13 Enrolled              -16-               LRB9100300RCksA
 1        controlled  substances  to  be  included  in  the program
 2        required under Section 316.
 3             (2) Design for the creation of the database required
 4        under Section 317.
 5             (3)   Requirements   for   the    development    and
 6        installation   of   on-line   electronic  access  by  the
 7        Department  to  information  collected  by  the   central
 8        repository.

 9        (720 ILCS 570/320 new)
10        Sec. 320.  Advisory committee.
11        (a)  The  Secretary  of  Human  Services  must appoint an
12    advisory committee to assist the Department  in  implementing
13    the  Schedule II controlled substance prescription monitoring
14    program created by Section 316  of  this  Act.  The  Advisory
15    Committee consists of prescribers and dispensers.
16        (b)  The  Secretary  of Human Services must determine the
17    number of members to serve on the  advisory  committee.   The
18    Secretary  must  choose  one  of  the members of the advisory
19    committee to serve as chair of the committee.
20        (c)  The  advisory  committee  may  appoint   its   other
21    officers as it deems appropriate.
22        (d)  The  members of the advisory committee shall receive
23    no compensation for their services as members of the advisory
24    committee but may be reimbursed  for  their  actual  expenses
25    incurred in serving on the advisory committee.

26        (720 ILCS 570/406) (from Ch. 56 1/2, par. 1406)
27        Sec. 406.  (a)  It is unlawful for any person:
28        (1)  who   is   subject   to  Article  III  knowingly  to
29    distribute or dispense a controlled substance in violation of
30    Sections 308 through 314 of this Act; or
31        (2)  who is a registrant,  to  manufacture  a  controlled
32    substance   not   authorized   by  his  registration,  or  to
 
SB13 Enrolled              -17-               LRB9100300RCksA
 1    distribute or dispense a controlled substance not  authorized
 2    by his registration to another registrant or other authorized
 3    person; or
 4        (3)  to  refuse  or  fail  to  make,  keep or furnish any
 5    record,  notification,  order  form,  statement,  invoice  or
 6    information required under this Act; or
 7        (4)  to  refuse  an  entry  into  any  premises  for  any
 8    inspection authorized by this Act; or
 9        (5)  knowingly to  keep  or  maintain  any  store,  shop,
10    warehouse,  dwelling,  building,  vehicle, boat, aircraft, or
11    other structure or place, which is resorted to  by  a  person
12    unlawfully possessing controlled substances, or which is used
13    for  possessing,  manufacturing,  dispensing  or distributing
14    controlled substances in violation of this Act.
15        Any person who violates this subsection (a) is guilty  of
16    a  Class  A  misdemeanor  for the first offense and a Class 4
17    felony  for  each  subsequent  offense.  The  fine  for  each
18    subsequent offense  shall  not  be  more  than  $100,000.  In
19    addition,  any  practitioner who is found guilty of violating
20    this subsection (a) is subject to suspension  and  revocation
21    of   his   professional  license,  in  accordance  with  such
22    procedures  as  are  provided  by  law  for  the  taking   of
23    disciplinary  action  with  regard  to  the  license  of said
24    practitioner's profession.
25        (b)  It is unlawful for any person knowingly:
26        (1)  to  distribute,  as  a  registrant,   a   controlled
27    substance  classified in Schedule I or II, except pursuant to
28    an order form as required by Section 307 of this Act; or
29        (2)  to  use,  in  the  course  of  the  manufacture   or
30    distribution of a controlled substance, a registration number
31    which is fictitious, revoked, suspended, or issued to another
32    person; or
33        (3)  to  acquire  or  obtain  possession  of a controlled
34    substance by misrepresentation, fraud, forgery, deception  or
 
SB13 Enrolled              -18-               LRB9100300RCksA
 1    subterfuge; or
 2        (4)  to  furnish false or fraudulent material information
 3    in, or omit any material information from,  any  application,
 4    report  or  other document required to be kept or filed under
 5    this Act, or any record required to be kept by this Act; or
 6        (5)  to make,  distribute  or  possess  any  punch,  die,
 7    plate,  stone  or  other  thing designed to print, imprint or
 8    reproduce the trademark,  trade  name  or  other  identifying
 9    mark, imprint or device of another, or any likeness of any of
10    the  foregoing, upon any controlled substance or container or
11    labeling thereof so as  to  render  the  drug  a  counterfeit
12    substance; or
13        (6)  to  possess  without  authorization,  official blank
14    prescription forms or counterfeit prescription forms; or
15        (7)  (Blank).  to  issue  a  prescription  or  fill   any
16    prescription  for  a  controlled  substance other than on the
17    appropriate lawful prescription form.  However, in  the  case
18    of  any  epidemic  or  a  sudden  or  unforeseen  accident or
19    calamity, the prescriber may issue a prescription on  a  form
20    other  than  the  official  prescription  form  issued by the
21    Department, where failure to issue such a prescription  might
22    result  in  loss  of  life  or  intense  suffering,  but such
23    prescription shall have endorsed thereon, by the  prescriber,
24    a statement concerning the accident, calamity or circumstance
25    constituting the emergency, the cause of which the unofficial
26    blank was used.
27        Any  person who violates this subsection (b) is guilty of
28    a Class 4 felony for the first offense and a Class  3  felony
29    for  each subsequent offense.  The fine for the first offense
30    shall  be  not  more  than  $100,000.   The  fine  for   each
31    subsequent offense shall not be more than $200,000.
32        (c)  A  person  who  knowingly  or intentionally violates
33    Section 316, 317,  318,  or  319  is  guilty  of  a  Class  A
34    misdemeanor.
 
SB13 Enrolled              -19-               LRB9100300RCksA
 1    (Source: P.A. 85-1287.)

 2        (720 ILCS 570/308 rep.)
 3        (720 ILCS 570/310 rep.)
 4        (720 ILCS 570/311 rep.)
 5        Section  10.   The  Illinois Controlled Substances Act is
 6    amended by repealing Sections 308, 310, and 311.

 7        Section 99.  Effective date.  This Act takes effect April
 8    1, 2000.

[ Top ]